Screener
Vaxcyte, Inc. PCVX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(320,622) | $(140,718) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,947 | 2,956 |
| Stock-based compensation expense | 37,964 | 30,615 |
| Amortization of operating lease right-of-use assets | 2,907 | 1,918 |
| Net accretion of discounts on investments | (3,112) | (4,913) |
| Unrealized foreign exchange loss (gain) | 2,201 | (6,617) |
| Changes in operating assets and liabilities: |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s stock-based comp?
- Vaxcyte, Inc. (PCVX) reported stock-based comp of $37.96M in Q1 2026.
- How has Vaxcyte, Inc.'s stock-based comp changed year-over-year?
- Vaxcyte, Inc.'s stock-based comp increased by 24.0% year-over-year, from $30.62M to $37.96M.
- What is the long-term trend for Vaxcyte, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s stock-based comp has grown at a 89.7% compound annual growth rate (CAGR), from $10.73M to $138.85M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Vaxcyte, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude